News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Boehringer Ingelheim Corporation Ohio Drug Plant Shut by U.S. on Quality Issues


2/1/2013 8:27:44 AM

Boehringer Ingelheim GmbH, the world’s largest family-owned drugmaker, agreed to stop production at an Ohio plant until it fixes manufacturing practices that led to about 40 product recalls in a decade. U.S. District Judge Lesley Wells in Cleveland today approved a consent decree against Boehringer’s Ben Venue Laboratories plant in Bedford, Ohio, and three company officers after quality assurance rules were violated, leading to particles found in injectable drugs, the Food and Drug Administration said in a statement. Marjorie Moeling, a spokeswoman for the Ingelheim, Germany-based drugmaker, didn’t immediately return a call or an e-mail requesting comment. Drugs produced by Ben Venue have been withdrawn about 40 times since 2002, reflecting “a continuing pattern of significant deviations from current good manufacturing practices,” the U.S. Justice Department said in a statement. Among the medicines was Sanofi’s Fludara leukemia therapy, pulled in February 2012 because it may not have been sterile. “The company’s failure to promptly address these problems put patients at risk of receiving poor quality drugs and compromises the availability of medically necessary products,” Melinda K. Plaisier, acting associate commissioner for regulatory affairs at the FDA, said in the statement. “This company continued to violate the law, and the FDA took action to help ensure that medicines that consumers rely on are safe, effective, and of high quality.”

Read at Bloomberg
Read at News Release
Read at Modern Healthcare


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES